Bilaal.Raja
Company record

SEER  Seer, Inc.

Trailing twelve months to 2026-03-31, as filed 2026-05-13 and not restated since.
Healthcare

Scale

Market cap
$125m
Revenue TTM
$15m
Net income TTM
$-70m
Free cash flow
$-50m
Composite score
39.8
Sector rank
#2985

Valuation

P / E
—
EV / EBITDA
—
EV / sales
-2.8
FCF yield
-40.04%
Yield vs 10-yr
-61.87pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-464.8%
EBITDA margin
-451.8%
ROE
-29.2%
ROIC
-99.6%
Revenue growth
-0.9%

Insider activity, last 90 days

Net open-market
$-0.04m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Since we were incorporated in 2017, we have devoted substantially all of our resources to research and development activities, including with respect to the Proteograph Product Suite, building our commercial infrastructure including manufacturing, operations, sales and marketing and service and support functions, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, becoming and being a publicly-traded company, and providing general and administrative support for these activities. …Seer, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →